No Data
No Data
CMA Accepts Google's Commitments On Third-Party Cookies
CMA Accepts Google's Commitments On Third-Party
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint
S&P 500, Nasdaq Rebound, as Nvidia, Tesla and Rest of Magnificent Seven Rally
The
Visa Q3 Profit Seen Dipping Amid Slowing, Albeit Resilient, Consumer Spending
The S&P 500 Typically Outperforms in July, Underperforms August-October - RBC Capital Markets
Cantor Fitzgerald Reiterates Overweight on Tesla, Maintains $230 Price Target
Cantor Fitzgerald analyst Andres Sheppard reiterates Tesla (NASDAQ:TSLA) with a Overweight and maintains $230 price target.